Cook Steven L. sold $55K of OMDA

Cook Steven L. (Chief Financial Officer) sold 2,900 shares of Omada Health, Inc. (OMDA) at an average of $19.02 ($19.00–$19.02) across 2 trades over 2026-06-24 to 2026-06-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cook Steven L.
Published Jun 26, 2026, 11:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure updates the insider activity record but does not introduce new operational or financial information. Any market reaction is likely limited to short-term sentiment around insider selling.

02

Market read

Traders may note the CFO’s ongoing selling activity, but the pre-arranged 10b5-1 nature and small dollar amount reduce decision impact.

03

What to watch

The article provides no information on performance, guidance, or changes in business fundamentals—so traders should avoid over-weighting the sale versus other catalysts.

Relevance 2/10Novelty 3/10Timing: after-hours/filing timestamp (2026-06-26) for the Form 4 disclosure

Background

This is an SEC Form 4 insider transaction: CFO Steven L. Cook sold 2,900 shares of Omada Health (OMDA) in two trades at ~$19.00–$19.02 under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CFO Steven L. Cook filed an open-market sale of 2,900 shares at ~$19.01 under a 10b5-1 plan, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale with modest dollar value (~$55k) and no accompanying fundamental catalyst or guidance change.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be purely mechanical (tax/compensation liquidity) and not a bearish signal.

Key entities

  • Omada Health, Inc.

    Subject of the Form 4 insider transaction; CFO Steven L. Cook sold shares under a 10b5-1 plan.

  • Steven L. Cook

    Omada Health CFO; executed open-market sales totaling ~$55.1k across 2 trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.